Stefan Stevanović

Active 1990–2023

Also published as
Stefan Stevanovic
130
Papers
23,640
Citations
86
h-index
128
i10-index

Citations

Citations per year for Stefan Stevanović1932: 2 citations1981: 1 citations1991: 4 citations1992: 9 citations1993: 24 citations1994: 42 citations1995: 86 citations1996: 81 citations1997: 116 citations1998: 142 citations1999: 150 citations2000: 165 citations2001: 172 citations2002: 222 citations2003: 181 citations2004: 203 citations2005: 236 citations2006: 190 citations2007: 179 citations2008: 148 citations2009: 154 citations2010: 163 citations2011: 123 citations2012: 124 citations2013: 156 citations2014: 172 citations2015: 191 citations2016: 199 citations2017: 188 citations2018: 188 citations2019: 565 citations2020: 751 citations2021: 883 citations2022: 715 citations2023: 641 citations2024: 622 citations2025: 305 citations2026: 18 citations1933–1980: no citations, so these years are not shown1982–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,640 citing papers, 26% of this breakdownGermany: 1,213 citing papers, 12% of this breakdownChina: 885 citing papers, 8.7% of this breakdownUnited Kingdom: 698 citing papers, 6.9% of this breakdownFrance: 367 citing papers, 3.6% of this breakdownItaly: 361 citing papers, 3.6% of this breakdownSwitzerland: 340 citing papers, 3.3% of this breakdownNetherlands: 327 citing papers, 3.2% of this breakdownCanada: 291 citing papers, 2.9% of this breakdownAustralia: 290 citing papers, 2.9% of this breakdownJapan: 279 citing papers, 2.7% of this breakdownSpain: 190 citing papers, 1.9% of this breakdown
0%26%Other 22.3%

Fields

  • Medicine35.9%
  • Immunology and Microbiology30.1%
  • Biochemistry, Genetics and Molecular Biology27.6%
  • Agricultural and Biological Sciences2.1%
  • Neuroscience1%
  • Chemistry0.8%
  • Other2.5%

Topics

  • Immunotherapy and Immune Responses11.5%
  • vaccines and immunoinformatics approaches7%
  • Immune Cell Function and Interaction5.4%
  • T-cell and B-cell Immunology4.9%
  • Cancer Immunotherapy and Biomarkers4%
  • CAR-T cell therapy research3.5%
  • Other63.7%

Coauthors

All papers

Open in search
  1. Actively personalized vaccination trial for newly diagnosed glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Löwer, Monika Stieglbauer, Cedrik M. Britten, David Capper, Marij J.P. Welters, Juan Sahuquillo, Katharina Kiesel, Evelyna Derhovanessian, Elisa Rusch, Lukas Bunse, Colette Song, Sandra Heesch, Claudia Wagner, Alexandra Kemmer-Brück, Jörg Ludwig, John C. Castle, Oliver Schoor, Arbel D. Tadmor, Edward Green, Jens Fritsche, Miriam Meyer, Nina N. Pawlowski, Sonja Dorner, Franziska Hoffgaard, Bernhard Rössler, Dominik Maurer, Toni Weinschenk, Carsten Reinhardt, Christoph Huber, Hans-Georg Rammensee, Harpreet Singh‐Jasuja, Uğur Şahin, Pierre-Yves Dietrich, Wolfgang Wick - Nature 2018 cited by 941

  2. A vaccine targeting mutant IDH1 in newly diagnosed glioma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2021 cited by 425

  3. HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2020 cited by 272

  4. SYFPEITHI: database for MHC ligands and peptide motifs

    Authors: , , , , - Immunogenetics 1999 cited by 2,326

  5. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2021 cited by 247

  6. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lena-Christin Gruber, David Rachfalski, Beate Preuß, Ilona Hagelstein, Melanie Märklin, Tamam Bakchoul, Cécile Gouttefangeas, Oliver Kohlbacher, Reinhild Klein, Stefan Stevanović, Hans-Georg Rammensee, Juliane S. Walz - Nature Immunology 2020 cited by 641

  7. A vaccine targeting mutant IDH1 induces antitumour immunity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2014 cited by 706

  8. Targeting of intracellular oncoproteins with peptide-centric CARs

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2023 cited by 75

  9. Tumor-Associated MICA Is Shed by ADAM Proteases

    Authors: , , , , , , , , - Cancer Research 2008 cited by 374

  10. Dermcidin: a novel human antibiotic peptide secreted by sweat glands

    Authors: , , , , , , , , , , , - Nature Immunology 2001 cited by 735

  11. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kosei Hirakawa, Hiroaki Tanaka, Stefan Stevanović, Jürgen Frisch, Andrea Mayer-Mokler, Alexandra Kirner, Hans-Georg Rammensee, Carsten Reinhardt, Harpreet Singh‐Jasuja - Nature Medicine 2012 cited by 784

  12. Improved Ribo-seq enables identification of cryptic translation events

    Authors: , , , , , , , , - Nature Methods 2018 cited by 230

  13. The immunopeptidomic landscape of ovarian carcinomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2017 cited by 199

  14. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins

    Authors: , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 cited by 633

  15. BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eicke Latz, Alexander N.R. Weber - The Journal of Experimental Medicine 2021 cited by 73

  16. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hans‐Georg Rammensee - Genome Medicine 2019 cited by 179

  17. RETRACTED ARTICLE: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2021 cited by 101

  18. Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 cited by 269

  19. Toll-like receptor 2 activation depends on lipopeptide shedding by bacterial surfactants

    Authors: , , , , , , , , , , - Nature Communications 2016 cited by 111

  20. MHCquant: Automated and Reproducible Data Analysis for Immunopeptidomics

    Authors: , , , , , , , , , , , - Journal of Proteome Research 2019 cited by 62

  21. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , - Brain 2012 cited by 201

  22. Biomimetic Remineralization of Carious Lesions by Self-Assembling Peptide

    Authors: , , , , , , - Journal of Dental Research 2017 cited by 169

  23. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry

    Authors: , , - Immunology 2018 cited by 116

  24. MHC ligands and peptide motifs: first listing

    Authors: , , - Immunogenetics 1995 cited by 1,652